Exhibit 2

AGREEMENT REGARDING THE JOINT FILING OF

SCHEDULE 13D

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D with respect to the Common Stock beneficially owned by each of them of Keros Therapeutics, Inc. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

Date: April 23, 2020

PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.
By :	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Chief Executive Officer
PONTIFAX (CAYMAN) IV, L.P.
By:	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Chief Executive Officer
PONTIFAX (ISRAEL) IV, L.P.
By:	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Chief Executive Officer
PONTIFAX (CHINA) IV L.P.
By:	/s/ Ran Nussbaum
Name:	Ran Nussbaum
Title:	Chief Executive Officer
PONTIFAX LATE STAGE FUND L.P.
By :	/s/ Asaf Shinar
Name:	Asaf Shinar
Title :	Chief Financial Officer
PONTIFAX LATE STAGE GP Ltd.
By :	/s/ Asaf Shinar
Name:	Asaf Shinar
Title :	Chief Financial Officer